CellCentric – $220M Financing for Inobrodib
CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development.
admin
Takeda TAK-881 Wins Pivotal Phase 2/3 in PID
Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease previously treated with immunoglobulin therapy, met its primary endpoint demonstrating pharmacokinetic comparability to HyQvia. The trial evaluated TAK-881…
Takeda – Rusfertide US Rights Deal
Protagonist Therapeutics has opted out of its 50:50 US profit-sharing agreement with Takeda for rusfertide, granting Takeda full US commercial rights in exchange for up to $475 million in near-term payments and substantial downstream…
Lilly – Ajax JAK2 Deal ($2.3B)
Eli Lilly has entered a definitive agreement to acquire Ajax Therapeutics in a deal worth up to $2.3 billion to secure AJ1-11095, a first-in-class Type II JAK2 inhibitor for myelofibrosis and polycythemia vera, positioning…
Intellia – CRISPR Therapy Hits Phase 3 Endpoint
Intellia Therapeutics reported that its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met its Phase 3 primary endpoint in hereditary angioedema, reducing swelling attacks by 87% versus placebo and advancing toward FDA submission.
CorMedix – Rezafungin Phase 3 (HSCT Prophylaxis)
CorMedix reported positive Phase 3 results from the ReSPECT trial for rezafungin (REZZAYO), demonstrating non-inferiority to standard antimicrobial regimens for prevention of invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients.
Compass – Bispecific Misses OS Endpoint
Compass Therapeutics reported that its DLL4xVEGF-A bispecific antibody, tovecimig, failed to meet the overall survival (OS) endpoint in a Phase 2/3 trial in biliary tract cancer, despite showing a statistically significant progression-free survival (PFS)…
Regeneron – MFN Drug Pricing Agreement
Regeneron has entered into a ‘most favored nation’ (MFN) drug-pricing agreement with the White House, aligning certain drug prices with Medicaid benchmarks. The move reflects increasing policy pressure on pharmaceutical pricing rather than a…
Pfizer – Ends Immunostimulatory Conjugate Program
Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities.
Merck – $1B Google AI Deal
Merck has entered a ~$1 billion enterprise agreement with Google Cloud to expand use of AI across its R&D and operational infrastructure, marking a major investment in AI-enabled drug development capabilities.
